Vise Technologies’s PTC Therapeutics PTCT Stock Holding History

Vise Technologies’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$698K	Sell	8,560 -1,282	-13%	-$92.6K	0.01%	974
2026 Q1	$748K	Hold	9,842	–	–	0.01%	690
2025 Q4	$748K	Buy	9,842 +756	+8%	+$54.9K	0.01%	695
2025 Q3	$558K	Sell	9,086 -855	-9%	-$44.5K	0.02%	627
2025 Q2	$486K	Buy	+9,941	New	+$472K	0.02%	660
2024 Q4	$461K	Sell	10,215 -672	-6%	-$28.8K	0.04%	462
2024 Q3	$404K	Sell	10,887 -3,429	-24%	-$115K	0.05%	360
2024 Q2	$438K	Buy	14,316 +1,168	+9%	+$37.8K	0.08%	248
2024 Q1	$382K	Buy	13,148 +340	+3%	+$9.52K	0.08%	246
2023 Q4	$353K	Buy	12,808 +2,140	+20%	+$48.9K	0.08%	239
2023 Q3	$239K	Buy	10,668 +1,673	+19%	+$62.2K	0.06%	286
2023 Q2	$366K	Buy	8,995 +473	+6%	+$23.1K	0.09%	220
2023 Q1	$413K	Buy	8,522 +444	+5%	+$20.3K	0.11%	193
2022 Q4	$308K	Buy	8,078 +1,306	+19%	+$54.3K	0.1%	230
2022 Q3	$340K	Buy	+6,772	New	+$332K	0.13%	195

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Vise Technologies's PTCT Position: Q2 2026 in Review

Vise Technologies reduced its PTC Therapeutics (PTCT) stake by 13% in Q2 2026, selling an estimated $92.6K and leaving 8,560 shares worth $698K. The position accounts for 0.01% of the portfolio, ranked #974.

Vise Technologies first reported a position in PTCT in Q3 2022 and has held it in 15 quarters since. The position peaked at $748K in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Vise Technologies held 8,560 shares of PTC Therapeutics worth $698K as of Q2 2026.
Vise Technologies sold 1,282 PTC Therapeutics shares in Q2 2026, an estimated $92.6K.
PTC Therapeutics made up 0.01% of Vise Technologies's portfolio in Q2 2026, its #974 holding.
Vise Technologies first reported a position in PTC Therapeutics in Q3 2022 and has held it in 15 quarters since.
Vise Technologies's PTC Therapeutics position peaked at $748K in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Vise Technologies's 13F filing for Q2 2026, filed 11 Aug 2026.